1ST BIOTHERAPEUTICS
1STBIO is dedicated to developing breakthrough therapies with a key value to provide novel medicines to patients. We are focused on discovery and development of innovative first-in-class therapeutic candidates with highly likelihood of clinical success. 1STBIO currently has 24 employees with expertise in biochemistry, medicinal chemistry, pharmacology, and business development. We are working as a core expertise team of drug discovery/development and are rigorously connected to R&D networking of academia, hospitals, industry, CRO’s and investors in Korea, China and US. Our ultimate goal is to use our experience and knowledge to discover and develop effective molecular therapeutics for patients.
1ST BIOTHERAPEUTICS
Industry:
Pharmaceutical Therapeutics
Address:
Seongnam, Kyonggi-do, South Korea
Country:
South Korea
Website Url:
http://www.1stbio.com
Status:
Active
Contact:
031) 8023-5333
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Nginx Sitelinks Search Box
Current Employees Featured
Founder
Official Site Inspections
http://www.1stbio.com Semrush global rank: 6.09 M Semrush visits lastest month: 1.33 K
- Host name: 62.110.229.35.bc.googleusercontent.com
- IP address: 35.229.110.62
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "1st Biotherapeutics"
About Us | 1ST Biotherapeutics
She spent 10 years in the public sector as the CEO of Korea National Enterprise for Clinical Trials (KoNECT), an organization established by the Korean government to advance the clinical …See details»
1ST Biotherapeutics
1STBIO was founded by experienced veterans in the life science industry with an aim to assemble a team with scientific, clinical, and business expertise. Since its inception, seasoned professionals in their respective fields have joined …See details»
1STBIO Company Profile 2024: Valuation, Funding & Investors
1STBIO General Information Description. Operator of a biotech company intended to develop a treatment for degenerative brain diseases. The company develops a pipeline of first-in-class …See details»
1st Biotherapeutics - Crunchbase Company Profile & Funding
1STBIO is dedicated to developing breakthrough therapies with a key value to provide novel medicines to patients. We are focused on discovery and development of innovative first-in …See details»
1st Biotherapeutics - Overview, News & Similar companies
1st Biotherapeutics contact info: Phone number: +82 3180235333 Website: www.1stbio.com What does 1st Biotherapeutics do? 1ST Biotherapeutics is a science-driven biopharmaceutical …See details»
1st Biotherapeutics, Inc. - Drug pipelines, Patents, Clinical
1STBIO is dedicated to forging new paths in the creation of innovative treatments aimed at providing patients with groundbreaking medications. The organization's focus is squarely on …See details»
Partnerships | 1ST Biotherapeutics
Our diverse base of collaborators and strategic partners enable us to accelerate our progress in developing innovative and novel therapies. We have forged a global network of alliances and …See details»
1ST Biotherapeutics, Inc., Announces Positive Phase I Data of c-Abl ...
Oct 18, 2022 For more information, please visit 1stbio.com. Contact 1ST Biotherapeutics, Inc. Bonjoon Goo / Minjung Won. Business Development and Corporate Strategy. …See details»
1st Biotherapeutics - VentureRadar
1STBIO is dedicated to developing breakthrough therapies with a key value to provide novel medicines to patients, with a focus on Neurodegenerative Diseases, Immuno-Oncology, and …See details»
R&D Pipeline | 1ST Biotherapeutics
Our research focuses on developing a broad portfolio of drug candidates across areas of significant unmet needs. The programs in our portfolio are derived from our profound scientific …See details»
1ST Bio - Company Profile - Tracxn
1ST Bio - Developer of therapies for treating neurodegenerative and immuno-oncology diseases. from 11 investors. Founded by Jamie Jae Eun Kim in the year 2016. 1ST Bio has 480 …See details»
1st Biotherapeutics - Company info. interviews, news
1STBIO is dedicated to developing breakthrough therapies with a key value to provide novel medicines to patients. We are focused on discovery and development of innovative first-in …See details»
Investors & Media | 1ST Biotherapeutics
Our science-driven strategy allows us to advance our programs with sound execution and ultimately bring long-term value to patients. Follow the journey of our dedicated scientists and …See details»
1ST Biotherapeutics, Inc. Announces First Patient Dosed in Phase …
Dec 14, 2023 [email protected] Tel. +82 31 8023 5332. Media Inquiries akampion Dr. Ludger Wess / Ines-Regina Buth Managing Partners [email protected] Tel. +49 40 88 16 59 64 / …See details»
FB-849 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 8, 2024 For more information, please visit 1stbio.com. Contact 1ST Biotherapeutics, Inc. [email protected] Tel. +82 31 8023 5332 Media Inquiries akampion Dr. Ludger Wess / Ines …See details»
1ST Biotherapeutics, Inc., Announces FDA Clearance of IND …
Dec 13, 2022 - Initiation of Phase 1/2 Clinical Trial Expected in Q1 2023 YONGIN, South Korea, December 13, 2022 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company …See details»
Patient-Derived Tumor Organoids for Guidance of Personalized …
Patients were previously diagnosed with high-grade glioma according to the current World Health Organization (WHO) criteria . On the basis of follow-up MRIs, tumor recurrence was suspected …See details»
1ST Biotherapeutics, Inc., Announces Positive Phase I Data of c-Abl ...
Oct 18, 2022 For more information, please visit 1stbio.com. 1ST Biotherapeutics, Inc., Announces Positive Phase I Data of c-Abl Inhibitor in Neurodegeneration - Compound …See details»
1ST BIO Therapeutics, 'first-in-class' drugs for preventing ...
Aug 9, 2017 1ST BIO Therapeutics envisages successful technology transfer for 4 pipelines, including neurodegenerative drugs, in a couple of years to comeSee details»
Disease Areas | 1ST Biotherapeutics
Neurodegenerative Diseases. FB-101 targets c-Abl, which has been shown to play a critical role in driving alpha-synuclein pathogenesis in Parkinson’s disease.See details»